Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

The documents show that blockbuster cancer drugs like pembrolizumab (brand Keytruda), osimertinib (brand Tagrisso), and ...

Keytruda, the world's top-selling drug with nearly $30 billion in revenue last year, is nearing key patent expirations from ...

Kazia Therapeutics (NASDAQ:KZIA) on Wednesday reported preliminary results from the first patient in its Phase 1b trial ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

The list recommending customs duty of 5% includes 74 drugs, while another suggesting full exemption has 69 drugs. A separate ...

Patients using steroids, especially at high-doses, before taking immune checkpoint inhibitors for non–small cell lung cancer ...

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care radiotherapy improves event-free survival in patients with resectable, locally ...

A promising clinical trial shows that a combination of paxalisib, pembrolizumab, and chemotherapy significantly reduces circulating tumor cells in metastatic triple-negative breast cancer.